ZK 200775

Product Description

ZK 200775 is a competitive AMPA/kainate antagonist. In rat cortical membranes, displays high affinity for [³H]-AMPA (K_i = 120 nM) and [³H]-CNQX (K_i = 32 nM) binding sites and low affinity for kainate and NMDA channel-associated binding sites (IC₅₀ values range from 2.5 to 11 μM). Inhibits currents induced by AMPA, Kainate and NMDA with IC₅₀ values of 21 nM, 27 nM, and > 1 μM respectively. Displays anxiolytic, anticonvulsant and muscle relaxant activity in vivo.

Solubility

Preparing Stock Solutions for ZK 200775

The following data is based on the product molecular weight 409.25

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.44 mL	12.22 mL	24.43 mL
5 mM	0.49 mL	2.44 mL	4.89 mL
10 mM	0.24 mL	1.22 mL	2.44 mL
50 mM	0.05 mL	0.24 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Sobolevsky X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009 PMID: 19946266
• Turski ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauman Proc.Natl.Acad.Sci.USA.
• Kosowski Nicotine-induced DA release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551n Pychopharmacology
• Elger Novel α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration. J.Med.Chem. 2005 PMID: 15999999